Vasomotor symptoms are not a minor inconvenience. According to the guideline, they are the most common symptoms associated with menopause, affecting up to 80 percent of women. They typically begin during perimenopause, the transitional phase before menstruation stops permanently, when declining and fluctuating levels of reproductive hormones destabilize the body’s temperature regulation. The result is the sudden, often intense sensation of heat known as a hot flash, frequently accompanied by sweating, flushing, and a racing heart, as well as night sweats that can drench sleepwear and interrupt rest. The guideline notes that these episodes can persist well into the postmenopausal years, and that their frequency and severity can disrupt daily activities and erode quality of life.

The physiological story behind vasomotor symptoms is rooted in estrogen. As ovarian function wanes, estrogen levels fall and fluctuate unpredictably, and this hormonal instability is thought to narrow the thermoneutral zone in the brain’s temperature-regulating machinery, making small shifts in core body temperature trigger full heat-dissipation responses. The consequences ripple outward: the guideline highlights that the same hormonal changes can contribute to sleep disturbance, weight fluctuations, anxiety, depression, and genitourinary symptoms, creating a cluster of complaints that often arrive together and compound one another. A woman whose nights are repeatedly broken by hot flashes may also face worsening mood and concentration problems the next day, which is why effective treatment of vasomotor symptoms can have benefits well beyond the episodes themselves.

In developing the recommendation, ACP drew on a related systematic review and meta-analysis, also published in Annals of Internal Medicine, that evaluated pharmacologic treatments for menopausal vasomotor symptoms. The college concluded that estrogen in combination with progestogen, and estrogen monotherapy for women without a uterus, had the most favorable profile of benefits compared with harms among the available options. The addition of progestogen for women with an intact uterus is a long-standing safety principle in hormone therapy, because unopposed estrogen can stimulate the uterine lining and increase the risk of endometrial problems; pairing it with progestogen protects the uterus while preserving estrogen’s effectiveness against hot flashes.

The guideline does not treat hormone therapy as the only option, and it lays out a clear sequence for women who cannot or do not wish to take estrogen. For patients who have contraindications to estrogen therapy or who do not tolerate it, ACP suggests serotonin-norepinephrine reuptake inhibitors, or SNRIs, as second-line treatment, specifically naming desvenlafaxine and venlafaxine. These medications, better known as antidepressants, have demonstrated the ability to reduce the frequency and severity of hot flashes through their effects on neurotransmitter signaling pathways that participate in temperature regulation.

If SNRIs are unsuitable or ineffective, the guideline moves to a third tier of options: a selective serotonin reuptake inhibitor, or SSRI, such as escitalopram or paroxetine; gabapentin, a medication originally developed for seizures and nerve pain that also dampens hot flashes; or a neurokinin receptor antagonist, abbreviated NKra, with elinzanetant and fezolinetant named as the agents in this class. The neurokinin receptor antagonists represent a distinctly newer approach, targeting the neuropeptide signaling pathway in the brain’s thermoregulatory circuitry that becomes overactive as estrogen declines. Their inclusion among third-line options reflects the recent arrival of these drugs as nonhormonal treatments designed specifically for vasomotor symptoms.

Beyond the specific drug rankings, ACP places strong emphasis on how treatment decisions should be made. The college advises clinicians to use an informed decision-making approach, discussing with each patient the benefits and harms of the available options, any contraindications, coexisting medical conditions, and the patient’s own values and preferences. Notably, the guideline also directs physicians to consider the financial burden of treatment and patients’ access to and availability of the various therapies, an acknowledgment that the best medication on paper is of little use if a patient cannot afford it or obtain it. This framing treats the choice of therapy as a collaborative process rather than a one-size-fits-all prescription.

ACP also draws attention to a quieter problem: many women never raise the topic at all. The college encourages physicians to ask their patients directly about their experience with menopausal vasomotor symptoms, because many women may not initiate these discussions on their own. Whether due to embarrassment, the cultural normalization of suffering through menopause, or the belief that nothing effective is available, women’s silence about hot flashes and night sweats can leave treatable symptoms unaddressed for years. By prompting clinicians to open the conversation, the guideline aims to close the gap between the large share of women affected and the smaller share who receive care.

The timing of the guideline reflects a broader shift in how the medical community views menopausal hormone therapy. After years in which safety concerns led many clinicians and patients to avoid estrogen-based treatment, accumulating evidence has allowed organizations to identify the women for whom hormone therapy offers the clearest net benefit, particularly those seeking relief from bothersome vasomotor symptoms. By naming estrogen therapy as first-line, ACP is signaling to internists and primary care physicians, who manage the majority of menopausal care, that withholding hormone therapy from appropriate candidates is no longer the default stance. The guideline’s tiered structure gives clinicians a practical pathway for the many patients who have contraindications to estrogen, such as those with a history of certain hormone-sensitive cancers or cardiovascular events, without leaving them without options.

For the roughly eight in ten women who will experience hot flashes or night sweats as they pass through the menopausal transition, the practical message of the new guideline is that effective treatments exist and that the choice among them can be tailored to individual health circumstances and preferences. Women with a uterus considering first-line therapy will receive estrogen plus progestogen; women without a uterus can receive estrogen alone; those who cannot take estrogen have a defined ladder of nonhormonal alternatives ranging from SNRIs to SSRIs, gabapentin, and neurokinin receptor antagonists. Equally important, the guideline reframes the clinical encounter itself, urging physicians to ask about symptoms that patients may not volunteer and to weigh cost and access alongside efficacy and safety. The full guideline and its accompanying evidence review are published in Annals of Internal Medicine, and together they provide the most current roadmap from the American College of Physicians for managing one of the most common and disruptive experiences in women’s health.

Subject of Research: Clinical guideline recommendations for pharmacologic treatment of menopausal vasomotor symptoms

Article Title: ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms

Article References: ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, vasomotor symptoms, hot flashes, hormone therapy, estrogen, progestogen, SNRI, SSRI, gabapentin, neurokinin receptor antagonist, clinical guideline, Annals of Internal Medicine

Vasomotor symptoms are among the most disruptive manifestations of menopause, caused principally by declining estrogen levels which disturb the thermoregulatory center in the hypothalamus. Traditional hormone therapy, while effective, can present significant risks and contraindications such as increased chances of stroke, breast cancer, and thromboembolic events. Elinzanetant diverges from these conventional therapies by selectively antagonizing neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors, thereby modulating neurokinin signaling pathways involved in thermoregulation without relying on estrogenic mechanisms.

Participants in the OASIS-3 trial received a daily dose of 120 mg elinzanetant or placebo over a 52-week period. By week 12, women treated with elinzanetant experienced a dramatic 73% reduction in the frequency and severity of hot flashes and night sweats, a robust outcome sustained throughout the entire duration of the study. These results not only validate earlier findings from previous OASIS-1 and OASIS-2 trials but also extend them by demonstrating the drug’s long-term efficacy and safety in a much larger, more diverse cohort.

Beyond the primary endpoints focusing on vasomotor symptom relief, the trial noted encouraging secondary outcomes. Participants reported improvements in sleep quality alongside enhanced overall quality of life. Although the study was not primarily powered to deeply investigate these secondary effects, the observations suggest a broader therapeutic potential for elinzanetant in alleviating menopause-related disturbances, especially those linked to sleep fragmentation and mood fluctuations arising from chronic night sweats and hot flashes.

Safety and tolerability measurements were rigorously assessed, including biomarkers of hepatic function and bone density scans. Unlike hormone therapy, which can negatively affect these parameters, elinzanetant demonstrated an absence of harmful impacts on liver function and bone mineralization. Common adverse events documented were minimal and generally mild, including transient sleepiness, fatigue, and headaches, indicating a favorable safety profile suitable for long-term administration.

The mechanism at the heart of elinzanetant’s clinical effect relies on its dual antagonism of NK1 and NK3 receptors, which are expressed in brain regions controlling temperature regulation and neuroendocrine signaling. Preclinical studies have implicated neurokinin B and substance P (ligands for NK3 and NK1 receptors, respectively) in the pathological modulation of the thermoregulatory setpoint during menopause. By blocking these receptors, elinzanetant appears to stabilize the hypothalamic thermostat, mitigating the erratic vasodilation events which manifest clinically as hot flashes.

Importantly, this drug represents a critical advancement for women who either cannot or choose not to undergo hormone replacement therapy (HRT) due to contraindications or personal preference. Various medical histories, including thrombophilia, breast cancer, or other estrogen-sensitive conditions, create substantial barriers to hormone treatments. Elinzanetant fills this therapeutic void by providing an efficacious, nonhormonal alternative that bypasses estrogen pathways altogether, potentially transforming the standard of care in menopausal symptom management.

In parallel with the OASIS-3 trial, the OASIS-4 study explored elinzanetant use in a subset of postmenopausal women undergoing breast cancer endocrine therapy, a population highly susceptible to severe vasomotor symptoms. Results mirrored those of OASIS-3, highlighting the drug’s versatility and safety across different clinical contexts where hormone therapy is unsuitable or contraindicated.

Despite these promising findings, regulatory approval remains pending. The U.S. Food and Drug Administration (FDA) has delayed its decision on elinzanetant, requesting additional data from Bayer, the pharmaceutical company behind the drug’s development. The comprehensive dataset from the extensive OASIS-3 trial represents a crucial component of the regulatory submission, providing strong evidence of sustained symptom relief and safety that could eventually pave the way for market approval.

As elinzanetant progresses towards potential commercial availability, the greater medical community anticipates the emergence of a new paradigm in menopause treatment. Current therapeutic options are limited, with most women enduring symptoms that substantially disrupt daily activities, sleep patterns, and psychological well-being. The advent of a nonhormonal, receptor-targeted drug offers hope for millions seeking effective relief with a more favorable risk-benefit profile.

This research was recently published in the prestigious journal JAMA Internal Medicine under open-access terms, facilitating widespread dissemination and engagement by clinicians, researchers, and patients alike. The article meticulously details the trial design, statistical analysis, efficacy outcomes, and safety data, underscoring the scientific rigor behind elinzanetant’s clinical evaluation and addressing critical questions related to menopausal symptomatology and therapeutic innovation.

JoAnn V. Pinkerton, MD, who leads midlife health initiatives at UVA Health and serves as emeritus executive director of the North American Menopause Society, emphasized the significance of this advancement. She underscored the need for nonhormonal options, highlighting the impact of vasomotor symptoms on women’s quality of life and the historical lack of effective alternatives. Dr. Pinkerton’s statements reflect the broader clinical imperative to diversify menopause management with targeted, well-tolerated agents like elinzanetant.

In conclusion, elinzanetant’s successful demonstration of efficacy across a one-year treatment horizon, coupled with its benign safety profile, marks a notable milestone in menopausal medicine. By intervening in neurokinin receptor pathways, this novel drug challenges the paradigm that estrogen replacement is the only viable strategy for treating vasomotor symptoms, introducing a mechanism-based approach aligned with precision medicine principles. Pending regulatory approval, elinzanetant could soon become a frontline therapeutic for millions of women globally, reshaping the landscape of menopausal healthcare with science-driven innovation.

Subject of Research: Gynecology, Menopause, Vasomotor symptoms, Nonhormonal treatment
Article Title: International Phase 3 Trial Demonstrates Sustained Efficacy of Elinzanetant for Menopausal Hot Flashes
News Publication Date: Not specified
Web References: https://dx.doi.org/10.1001/jamainternmed.2025.4421
References: Pinkerton JV, et al. OASIS-3 Trial Results. JAMA Internal Medicine, 2025.
Image Credits: UVA Health
Keywords: Gynecology, Menopause, Vasomotor symptoms, Neurokinin receptor antagonist, Elinzanetant, Nonhormonal therapy, Hormone replacement alternatives, Clinical trial, Pharmacology, Drug development, Breast cancer endocrine therapy, Quality of life